On April 27, 2022, the Competition Bureau announced that it has reached a settlement agreement with NuvoCare Health Sciences Inc and its founder (collectively “NuvoCare”), who were found to have made marketing claims that gave a false or misleading impression about their weight loss products.
Under paragraph 74.01(1)(b) of the Competition Act, a person cannot make a claim about a product’s performance, efficacy or length of life unless the claim is based on an adequate and proper test. The Competition Bureau’s investigation concluded that NuvoCare’s weight loss claims were not supported by adequate and proper testing.
As part of the settlement, NuvoCare agreed to pay $100,000 in penalties, change/remove all weight loss claims made about their products, and establish a corporate compliance program to prevent future deceptive marketing issues.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance group.
Related Publications & Articles
-
New Division 11 of the Food and Drug Regulations: Public or Canadian Armed Forces Health Emergencies - Drugs for Immediate Use or Stockpiling
On February 15, 2023, Regulations Amending Certain Regulations Concerning the Sale of Drugs (Public or Canadian Armed Forces Health Emergencies) came into force.Read More -
Minister of Health announces National Strategy for Drugs for Rare Diseases
On March 22, 2023, the Minister of Health announced the first-ever National Strategy for Drugs for Rare Diseases.Read More -
Permanent regulatory framework for COVID-19 medical devices now in force
On February 22, 2023, amendments to the Medical Devices Regulations came into force that create a permanent regulatory framework for COVID-19 medical devices: Regulations Amending the Medical Devices ...Read More